Facebook Linkedin

Bold Therapeutics

Bold Therapeutics, based in Vancouver, British Columbia, is a clinical-stage oncology company focused on developing BOLD-100, a ruthenium-based small molecule therapeutic, that appears to significantly enhance the activity of a wide range of other anti-cancer therapies by disabling a critical and previously untargeted cancer resistance, survival and proliferation pathway. Based on compelling preclinical and early clinical results, Bold Therapeutics is focusing its development efforts on some of the most challenging cancer indications where existing therapies are largely ineffective, resulting in a significant unmet medical need.

Centre de santé Tulattavik de l’Ungava

The mission of the UTHC is to provide safe, accessible and quality health and social services to the seven Inuit communities of the Ungava Bay Coast, and rehabilitation services to the fourteen Inuit communities of Nunavik

CISSS du Bas-Saint Laurent (Rimouski)

The Centre intégré de santé et de services sociaux du Bas-Saint-Laurent serves a population of 200,000 people spread over an area of 22,185 km2 from La Pocatière to Les Méchins. Its 42 points of service have nearly 7,500 employees and 580 doctors, dentists and pharmacists. In addition to providing healthcare and social services, the center participates in therapeutic clinical research in several medical fields, including oncology, rheumatology, cardiology, nephrology and microbiology-infectiology.